Letters to the Editor

[18F]Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Department of Internal Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Department of Internal Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Department of Internal Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Department of Internal Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Department of Medicine III Hematology, Oncology and Palliative Care, University Hospital, Rostock
Department of Internal Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden
Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Institute and Polyclinic for Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC) Dresden: a partnership between German Cancer Research Center (DKFZ), Heidelberg; Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology and Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
Department of Internal Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Department of Internal Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; National Center for Tumor Disease (NCT), Dresden
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC) Dresden: a partnership between German Cancer Research Center (DKFZ), Heidelberg; Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology and Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
Haematologica Early view May 21, 2026 https://doi.org/10.3324/haematol.2026.300672